Sanolium AB interim report April - June 2023

Report this content

Revenue in the second quarter amounted to 273.0 MSEK, representing a growth of 24.4%

CEO´s comment

Cambio continues to take steps on the journey to implement our strategy and to digitize health and social care in our prioritized markets. The second quarter has been characterized by continued build-up of our business within key customer groups.

For Sussa Samverkan, one of our major customer groups consisting of 9 Swedish regions, we have passed the Acceptance Test 2 in April, meaning that our solution has had the final acceptance from our customers. This means that we can now continue to work closely with the customer group to support them going live during 2024. Read more in the attached report.

Revenue in the second quarter amounted to 273.0 MSEK, representing a growth of 24.4%

Q2, April - June 2023

January - June 2023

  • Revenue amounted to 273.0 (219.5) MSEK in the second quarter, representing a growth of 24.4%
  • Adjusted EBITDA amounted to 48.4 (61.0) MSEK, representing a decrease of -20.6%
  • Income before tax amounted to -66.0 (11.1) MSEK
  • Net income per share was negative (0.05) SEK
  • Revenue during January – June amounted to 517.1
(424.8) MSEK
  • Adjusted EBITDA amounted to 88.4 (119.2)
  • Income before tax amounted to -95.5 (38.8) MSEK
  • Net income per share was negative (0.19) SEK

For further information, please contact: 

Rami Avidan
CEO

+46 070 793 483 
rami.avidan@cambio.se

Johannes Fabó
CFO
+46 730 599 368
johannes.fabo@cambio.se

Sanolium AB, parent of the Cambio Group (“Cambio” or “the Company”) operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.

Prenumerera